Stephen Squinto, Alexion

Stephen Squinto, Alexion ($ALXN)
2012 pay package: $4.33 million
2011 pay package: $3.68 million
Change: +17.66%
2012 Compensation: $540,000 in salary; $600,000 in bonus; $1.02 million in stock awards; $2.15 million in option awards; $600,000 in pension growth; $15,608 in other compensation

Before co-founding Alexion with CEO Leonard Bell in 1992, Stephen Squinto worked in drug discovery at Regeneron ($REGN) and served as an assistant professor of biochemistry and molecular biology at Louisiana State University Medical Center. After he and Bell started the company, Squinto led the program that resulted in Soliris' approval for patients with atypical hemolytic uremic syndrome.

As the world's most expensive therapy, Soliris has created an amazing narrative for the company, giving it a reputation as a global leader in ultrarare diseases. And that, in turn, has pushed its market cap to an amazing $22.7 billion.  

Soliris, the company's only branded drug and sole provider, has been branching out to treat other diseases, and most recently won approval for neuromyelitis optica, a rare disorder of the central nervous system. The drug is also in trials as a kidney transplant treatment. Alexion has other drug prospects in the pipeline, too; it's working on a new treatment for hypophosphatasia, a rare metabolic bone disease, and developing therapies for inflammatory disorders.

Last spring Squinto was replaced as R&D chief by Martin Mackay, who had just been booted from AstraZeneca ($AZN) by its new CEO after only a short run in that post. But far from leaving the company, Squinto was promoted to chief of global operations. 

For more:
Special Report: Soliris - Top 20 orphan drugs by 2018
Regeneron exec tops list of highest-paid biotech R&D officers
Analysts continue to pour cold water on hot Alexion buyout rumors
Booming Alexion looks to Ensemble platform for ultrarare disease programs

-- Skye Toor

Stephen Squinto, Alexion
Read more on

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.